InvestSMART

Imricor Medical Systems Inc (ASX: IMR) - Announcements

Current share price for IMR : $2.010 0.04 (1.95%)+

ASX company news and announcements for Imricor Medical Systems Inc (IMR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imricor Medical Systems Inc (IMR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imricor Medical Systems Inc (IMR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imricor Medical Systems Inc (IMR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$721 Appendix 3Y - SW 12 Jun 2024 10:57AM $0.440 $2.010 risen by 356.82%
$721 Notification regarding unquoted securities - IMR 12 Jun 2024 10:53AM $0.440 $2.010 risen by 356.82%
$721 Appendix 3Y - AM 27 May 2024 9:06AM $0.445 $2.010 risen by 351.69%
$721 Appendix 3Y - MT 27 May 2024 9:06AM $0.445 $2.010 risen by 351.69%
$721 Appendix 3Y - PM 27 May 2024 9:05AM $0.445 $2.010 risen by 351.69%
$721 Appendix 3Y - Purchase of Shares by Chair 24 May 2024 9:14AM $0.445 $2.010 risen by 351.69%
$721 Application for quotation of securities - IMR 22 May 2024 9:17AM $0.445 $2.010 risen by 351.69%
$721 Results of Meeting 15 May 2024 9:51AM $0.455 $2.010 risen by 341.76%
$721 Annual Stockholder Meeting Presentation Slides 15 May 2024 8:29AM $0.455 $2.010 risen by 341.76%
$721 Annual Meeting of Stockholders Chair's Address 15 May 2024 8:28AM $0.455 $2.010 risen by 341.76%
$721 Swissmedic Approval for VISABL-AFL Clinical Trial at CHUV 9 May 2024 9:19AM $0.480 $2.010 risen by 318.75%
$721 Appendix 3Y - PM 8 May 2024 11:30AM $0.500 $2.010 risen by 302%
$721 Release from Voluntary Escrow 2 May 2024 8:25AM $0.470 $2.010 risen by 327.66%
$721 Q1 CY24 Quarterly Results Investor Presentation 30 Apr 2024 8:47AM $0.490 $2.010 risen by 310.20%
$721 Imricor Q1 CY24 Quarterly Activities Report and Appendix 4C 30 Apr 2024 8:45AM $0.490 $2.010 risen by 310.20%
$721 Imricor Q1 CY24 Webinar Notification 23 Apr 2024 8:49AM $0.520 $2.010 risen by 286.54%
$721 Notification of cessation of securities - IMR 12 Apr 2024 1:14PM $0.535 $2.010 risen by 275.70%
$721 First Order Received from Dubrava University Hospital 11 Apr 2024 9:52AM $0.550 $2.010 risen by 265.45%
$721 Notification regarding unquoted securities - IMR 10 Apr 2024 4:20PM $0.550 $2.010 risen by 265.45%
$721 ANSM Approval for VISABL-AFL Clinical Trial at ICPS 10 Apr 2024 10:06AM $0.510 $2.010 risen by 294.12%
$721 Notice of Annual Stockholders Meeting and CDI Voting Form 9 Apr 2024 8:56AM $0.550 $2.010 risen by 265.45%
$721 Appendix 4G and Corporate Governance Statement 9 Apr 2024 8:55AM $0.550 $2.010 risen by 265.45%
$721 Annual Report to shareholders 9 Apr 2024 8:54AM $0.550 $2.010 risen by 265.45%
$721 Cleansing Notice 8 Apr 2024 1:03PM $0.555 $2.010 risen by 262.16%
$721 Application for quotation of securities - IMR 8 Apr 2024 12:22PM $0.555 $2.010 risen by 262.16%

176 - 200 of 596 results

Page 8 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.